GlassScriptPhysician profile
Sarah Grekin
NPI 1326205006
$12,831.21
in general payments reported to CMS, 2019-2025
22 companies · $2,049 in 2025
The $2,049 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $484 · 2021: $1,181 · 2022: $1,685 · 2023: $4,904 · 2024: $2,029 · 2025: $2,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,372 · Consulting Fee: $2,500 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,371.65 |
| Consulting Fee | $2,500.00 |
| Education | $109.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $2,870.07 | 2022-2024 | Vtama |
| Abbvie INC. | $1,981.14 | 2019-2025 | |
| Lilly USA, LLC | $1,119.30 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,109.50 | 2019-2025 | Dupixent |
| Genzyme Corporation | $898.31 | 2020-2025 | |
| Leo Pharma INC. | $836.14 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $530.09 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $460.38 | 2019-2025 | |
| Incyte Corporation | $459.43 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $432.56 | 2020-2025 | Ilumya, Winlevi |
| Ucb, INC. | $425.77 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $351.32 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $345.98 | 2020-2025 | |
| Amgen INC. | $329.61 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $254.25 | 2021-2025 | Simponi, Simponi Aria, Stelara |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $159.72 | 2019-2023 | Jublia |
| Sanofi-Aventis U.S. LLC | $78.50 | 2020-2021 | |
| Genentech USA, INC. | $70.74 | 2020-2025 | Xolair |
| Dermira, INC. | $36.22 | 2019 | |
| Mallinckrodt Hospital Products INC. | $31.46 | 2025 | Acthar |
| Biofrontera INC. | $28.04 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $22.68 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Grekin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.